A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

Inclusion Criteria:

• Is willing and able, in the opinion of the Investigator, to understand and complywith protocol requirements, including the following: lifestyle considerations andrestrictions, adherence to contraception guidance, adherence to actigraphy and diaryrequirements, if receiving treatment for OSA, adherence to primary OSA therapy overthe 30 days prior to Visit 1, and throughout the study, including during overnightvisits.

• Meets the diagnostic criteria of NT2 according to ICSD-3-TR guidelines, confirmed bydiagnostic evaluations (either PSG/MSLT).

Exclusion Criteria:

• Has another comorbid sleep disorder or condition that may influence the sleep-wakecycle.

• Has a history or presence of other clinically significant (treated or untreated)illness, disease, abnormality, or surgical procedure that, in the opinion of theInvestigator, might compromise participant safety, interfere with any studyassessment, or affect the participant's ability to complete the study.

• Is currently enrolled in another interventional clinical trial or has received anyinvestigational drug or used any interventional investigational device within 30days prior to Visit 1. Participants previously enrolled in Study ALKS 2680-202 arenot eligible for enrollment.

• Is currently pregnant, breastfeeding, or is planning to become pregnant during thestudy